FeesSafety
Pluang+

First Advantage prices $21.8/share secondary offering of 15M shares by Silver Lake funds.

Company Fundamentals
10 Nov 2026, 14:40 WIB
GlobeNewsWire
View Source
Neutral
First Advantage prices $21.8/share secondary offering of 15M shares by Silver Lake funds.

First Advantage Corporation announced the pricing of a secondary offering of 15 million common shares by Silver Lake Group investment funds at $21.80 per share. The company itself is not selling shares and will not receive proceeds; all proceeds go to the selling stockholder. The offering is expected to close around November 12, 2026, with Barclays Capital and J.P. Morgan Securities acting as underwriters. This move allows Silver Lake funds to liquidate part of their holdings without diluting First Advantage's shares.

First Advantage's secondary stock offering is the subject, with this data providing market context. For readers following Technology-sector stocks, 45 of 150 US stocks rose and 99 fell today on Pluang. Notable movers include QUBT at USD 6.58 with a -4.08% change, TTWO at USD 215.26 up 3.79%, and YOU at USD 56.86 up 3.21%, as of Nov 10, 2026 19:03 WIB.

More News

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...

Market News
Neutral
1 hour ago
Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...

Market News
Bullish
1 hour ago
PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...

Company Fundamentals
Bullish
1 hour ago
Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...

Company Fundamentals
Bullish
1 hour ago
Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App